WuXi Biologics (Cayman) Inc
02269
Company Profile
Business description
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
Contact
No. 108, Meiliang Road
Mashan Binhu District
Wuxi214092
CHNT: +86 51085353482
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12,435
WuXi Biologics (Cayman) Inc News & Analysis
stocks
3 top stocks for Asia
Fund managers say these are the themes to consider when looking for stocks in the Asia region
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.90 | 57.90 | -0.68% |
| CAC 40 | 8,072.38 | 127.33 | -1.55% |
| DAX 40 | 22,572.89 | 574.13 | -2.48% |
| Dow JONES (US) | 43,191.24 | 649.67 | -1.48% |
| FTSE 100 | 8,815.20 | 56.11 | -0.63% |
| HKSE | 22,941.77 | 64.50 | -0.28% |
| NASDAQ | 18,350.19 | 497.09 | -2.64% |
| Nikkei 225 | 37,331.18 | 454.29 | -1.20% |
| NZX 50 Index | 12,469.71 | 80.34 | -0.64% |
| S&P 500 | 5,849.72 | 104.78 | -1.76% |
| S&P/ASX 200 | 8,198.10 | 47.60 | -0.58% |
| SSE Composite Index | 3,324.21 | 7.28 | 0.22% |